Recon: Sanofi to help manufacture Moderna vaccine; EU sues AZ over vaccine supply issues

• US ends J&J COVID-19 vaccine pause; shots to resume immediately (Reuters) (STAT) (FDA)
• Sanofi to Help Make Moderna Covid-19 Vaccine for US (WSJ) (Press)
• Millions Are Skipping Their Second Doses of Covid Vaccines (NYTimes)
• FDA lifts hold on UniQure gene therapy study after review of cancer case (BioPharmaDive) (Endpoints)
• FDA to scrutinize unproven cancer drugs after 10-year gap (AP)
• FDA says Voyager can trek on as it removes trial hold for Huntington's gene therapy test (Fierce)
• CEO of vaccine maker Emergent sold $10 million in stock before company ruined Johnson & Johnson doses (Washington Post)

• US to share AstraZeneca shots with world after safety check (AP)
• EU sues AstraZeneca over breach of COVID-19 vaccine supply contract (Reuters)
• Biotech behind AstraZeneca vaccine aims to raise $117m at IPO (FT)
• Moderna vaccine to be reviewed for WHO emergency listing on April 30 - WHO spokesman (Reuters)
• Health Canada to start real-time review of Medicago COVID-19 vaccine (Reuters)
• EMA Says Yes To Eight New Medicines, Holds Fire On Others (Pink Sheet) (EMA)
• AstraZeneca vaccines sent to Mexico from Baltimore plant safe - deputy health minister (Reuters)
• Health Canada finds Astrazeneca COVID-19 vaccines from Baltimore plant safe, of high quality (Reuters)
• South African study using J&J vaccine will resume on Wednesday (Reuters)
• UK lawmakers call for PM Johnson to publish big pharma lobbying messages (Reuters)
• Israel examining heart inflammation cases in people who received Pfizer COVID shot (Reuters)

• South Korea’s Moon to meet Novavax CEO on vaccine production (Korea Herald)
• Vaccine makers say IP waiver could hand technology to China and Russia (FT)
• FDA says health care workers should stop reusing N95 masks (The Hill)
• U.S. to provide vaccine components, medical supplies as India battles COVID-19 spike (Reuters)
• India's federal government won't import vaccines, leaving it to states (Reuters)
• Moderna applies for emergency COVID-19 vaccine use in the Philippines (Reuters)
• Japan PM Mulls Legal Revision on Trial Requirement for Vaccines (PharmaJapan)
• S.Korea signs with Pfizer for additional 40 mln COVID-19 vaccine doses (Reuters)
• Malaysia says AstraZeneca vaccine safe, will be used for over 60s (Reuters)

• GlaxoSmithKline boss Dame Emma Walmsley set to face test of strategy (The Times)
• The price of a Vertex cystic fibrosis treatment stirs anger in Australia (STAT)
• ADC Therapeutics scores FDA approval for anti-CD19 blood cancer med Zynlonta (Fierce) (FDA)
• Sanofi starts off 'pipeline-in-a-product' rilzabrutinib in rare skin disease, but eyes bigger prize (Fierce)
• As­traZeneca and Sanofi tout break­through in €645M al­liance against lead­ing cause of in­fant death (Endpoints)
• FDA gives Ax­some speedy re­view for de­pres­sion drug, while oth­er in­di­ca­tions wait in the wings (Endpoints)
• AstraZeneca drives biomarker testing with a string of efforts—and a new leader (Fierce)
• Vertex picks a horse in race for opioid painkiller replacement (Fierce)
• Regeneron CEO Schleifer, chief scientist Yancopoulos bag massive $270M payday (Fierce)
• Christoph West­phal and the crew at No­var­tis-backed TScan aren't wait­ing to take their pre­clin­i­cal TCR pitch to Nas­daq (Endpoints)

• DJO Global continues string of orthopedic acquisitions with purchase of device maker MedShape (Fierce)
• Philips raises guidance as elective procedures exceed pre-pandemic levels (MedtechDive)
• J&J Device Businesses Return To Growth Led By Electrophysiology And Surgery (MedtechInsight)
• Swiss Medtechs Demand Renewed Negotiation Efforts As Latest EU Talks Falter (MedtechInsight)
• SMEs Buffeted About By EU MDR Delays Will Not Be Able To Financially Sustain Products (MedtechInsight)
• Cordis Recalls Precise PRO Rx US Carotid System Due to Risk of Separation in Device During Use (FDA)

• $1 Million in Toxic Bleach Sold as ‘Miracle’ Cure, Officials Say (NYTimes) (FDA)
• The Fifth Circuit Addresses Pay-for-Delay Agreements: Money for Nothing (and Patent Settlements for Free?) (FDA Law Blog)
• What Opioid Crisis? Drugmakers Test Bold Claim In Calif. Trial (Law360)
• Gilead, Shire Beat FCA Suits In NJ Over Marketing Programs (Law360)
• UK Judge Won't Invalidate Alcon's Glaucoma Treatment Patent (Law360)
• Fed. Circ. Won't Rehear Amgen Drug Patent Fight (Law360)
• DC Circ. Struggles With FDA Stance Over Electric Shock Ban (Law360)